使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day everyone and welcome to the ICN Pharmaceuticals third quarter 2002 earnings results conference call. Today's conference is being recorded. At this time, for opening remarks and introductions, I would like to turn the call over to Mr. Greg Keever, Executive Vice-President, General Counsel and Corporate Secretary for ICN. Please go ahead, sir.
各位大家好,歡迎參加 ICN Pharmaceuticals 2002 年第三季財報結果電話會議。今天的會議將被錄音。現在,為了開場致詞與介紹,我想把電話交給 ICN 的執行副總裁、總法律顧問兼公司秘書 Greg Keever 先生。先生,請開始。
- Executive Vice-President, General Counsel and Corporate Secretary
- Executive Vice-President, General Counsel and Corporate Secretary
Thank you. I would like to welcome everyone to today's call.
謝謝。我想歡迎各位參加今天的電話會議。
Before we begin the call, I would like to read to you the safe harbor statement under the Private Securities Litigation Reform Act of 1995. The statement is as follows: this presentation contains forward-looking statements that involve risks and uncertainties including, but not limited to, projections of future sales, operating income, returns on invested assets, regulatory approval processes, competition from generic products, marketplace acceptance of the company's products, success in the company's strategic repositioning initiatives and the ability of management to execute them, success with the company's on-going inventory reduction program and other cost cutting measures and other risks detailed from time to time in the company's Securities and Exchange Commission filings.
在我們開始之前,我想向各位宣讀 1995 年《私人證券訴訟改革法案》下的安全港聲明。聲明如下:本簡報包含前瞻性陳述,涉及風險與不確定性,包括但不限於:對未來銷售、營業利益、投資資產報酬的預測;法規核准流程;學名藥產品的競爭;市場對本公司產品的接受度;本公司策略性重新定位計畫及管理階層執行該等計畫的能力之成效;本公司持續進行的庫存降低計畫及其他成本削減措施之成效;以及本公司不時於向美國證券交易委員會(SEC)申報文件中所詳述的其他風險。
Joining us on the call today are Robert O'Leary, Chairman and Chief Executive Officer, Adam Jerney, President and Chief Operating Officer, John Giodarni, Chief Financial Officer, Phil , Treasurer, , Controller and Randy Thurman, an ICN director, all of whom will be available to answer questions during the Q&A Section.
今天與會者包括 Robert O'Leary(董事長兼執行長)、Adam Jerney(總裁兼營運長)、John Giodarni(財務長)、Phil(財務主管)、(會計主管)以及 ICN 董事 Randy Thurman;在問答環節中,他們都將可供回答問題。
Now, I'd like to turn over the call to Mr. O'Leary.
現在,我想把電話交給 O'Leary 先生。
o'leary: Thank you, Greg. Welcome to all of you too and thank you for joining us today. Please bear with us, we have a lot to share with you this morning. I'd like to apologize in advance for the length of this presentation. We're very glad to be with you and to be in a position to begin sharing with you the strategic vision for ICN.
O'Leary:謝謝你,Greg。也歡迎各位,並感謝大家今天加入我們。請各位多包涵,今天早上我們有很多內容要與各位分享。我先為本次簡報的篇幅致歉。我們很高興能與各位同在,也很高興能開始與各位分享 ICN 的策略願景。
In the short four and a half months since the election of the new board members, we have accomplished a great deal. We've been very busy working on a strategic direction for the company and the management changes that we are reporting to you today. Let me, of course, begin the call by saying that I'm very pleased to be joining ICN as its full guiding Chief Executive Officer.
在新任董事成員當選後短短四個半月內,我們已完成了許多工作。我們一直非常忙碌,致力於制定公司的策略方向,以及我們今天要向各位報告的管理層變動。當然,讓我先在電話會議一開始就表示,我非常高興能以正式的領導執行長身分加入 ICN。
I'm excited about the opportunity and about the prospects for this company. As you know, we have also announced the appointment of two new executives at ICN and it is a genuine pleasure to have professionals of this caliber joining the team. I have invited Randy Thurman, currently Chairman and Chief Executive Officer of Viasys Healthcare Inc., and the former President and CEO of Pharmaceuticals and who has served on the executive committee here at ICN and does - has served as the Chairman of the search committee of ICN's board, to join us on the call today.
我對這個機會以及公司前景感到振奮。如各位所知,我們也已宣布任命 ICN 兩位新高階主管,能有如此水準的專業人士加入團隊,確實令人非常欣喜。我邀請了 Randy Thurman 先生——現任 Viasys Healthcare Inc. 董事長兼執行長,亦曾任Pharmaceuticals 的總裁暨執行長,並曾在 ICN 擔任執行委員會成員,且—也曾擔任 ICN 董事會搜尋委員會主席——今天一同參與本次電話會議。
Randy has played a key roll in these executive appointments and he can share with you his perspective not only as a board member but also as someone who has many years of experience in the pharmaceutical industry. I'll turn the call over to Randy for a few brief remarks then join you gain to talk about our strategic redirection and third quarter earnings.
Randy 在這些高階主管任命中扮演了關鍵角色;他不僅能以董事身分,也能以擁有多年製藥產業經驗的人士角度,與各位分享他的觀點。我先把電話交給 Randy 做幾點簡短的說明,之後我會再回來與各位談談我們的策略轉向與第三季盈餘。
Randy is joining us on the phone from the East Coast and will be available to answer questions later in the Q&A session. Randy.
Randy 目前從美國東岸以電話加入,稍後在問答環節也將可供回答問題。Randy。
- Chairman of the Board, Viasys
- Chairman of the Board, Viasys
Thank you Rob. I'm very glad that I can represent the board of directors of ICN today to offer some insight into these very critical appointments and the new direction of ICN. When we set out four and a half months ago to find a new Chief Executive Officer and Executive Management Team for ICN, we knew the company needed the kind of leaders who would be able to quickly set a new course for the company and redirect its employees.
謝謝你,Rob。我很高興今天能代表 ICN 董事會,就這些極為關鍵的任命以及 ICN 的新方向提供一些見解。四個半月前,當我們著手為 ICN 尋找新的執行長與高階管理團隊時,我們知道公司需要能夠迅速為公司設定新航向並重新引導員工的領導者。
And whose sole focus would be on driving shareholder value. Indeed, that's why the new electors were elected. We knew that ICN needed executives who would be home in a fast paced environment that demanded quick and dramatic change. We didn't have to go very far to find the kind of leadership needed at the CEO level.
而且其唯一重點將是推動股東價值。事實上,這也是新當選董事之所以當選的原因。我們知道 ICN 需要能夠適應快節奏環境、並能因應快速且劇烈變革需求的高階主管。在執行長層級,我們不必走得太遠就找到了所需的領導人選。
On behalf of the board, I am very pleased to have Rob remain and to take the helm as ICN's Chief Executive Officer. Rob has worked tirelessly in four and a half months as interim Chairman and CEO, taking control at a time when investor confidence in the company was very low and steering the company through an earnings warning and a subsequent comprehensive strategic review of all of ICN businesses.
我代表董事會,非常高興 Rob 願意留下並掌舵,擔任 ICN 的執行長。在四個半月內,Rob 以代理董事長兼執行長身分不懈努力;他在投資人對公司信心非常低落之際接手,帶領公司度過盈餘預警,並隨後對 ICN 所有業務進行全面性的策略檢視。
Most importantly, Rob has the kind of vision that ICN needs to lead it to a new era as he and the new executive team begin to implement the board's new strategic direction. I've known Rob for years, and participated in recruiting him to the slate of new directors. Rob O'Leary is one of the most experienced healthcare executives in all of America. Having served as Chief Executive Officer of six different companies in his 28 year CEO career. Rob has most often been recruited to restructuring situations where tough-mindedness, decisiveness and leadership are at a premium.
最重要的是,Rob 具備 ICN 所需要的願景,能帶領公司邁向新時代;他與新的高階管理團隊正開始落實董事會的新策略方向。我認識 Rob 多年,也參與招募他加入新董事名單。Rob O'Leary 是全美最具經驗的醫療保健產業高階主管之一。在他 28 年的執行長職涯中,曾擔任六家不同公司的執行長。Rob 最常被延攬至需要重整的情境,在那裡,堅定、果斷與領導力尤為重要。
He has compiled an enviable record of accomplishments, most notably is highly visible and successful that will be experience at American Medical International. Always focused on creating shareholder value, Rob has emphasized that same discipline in four and a half short months at ICN.
他累積了令人稱羨的成就紀錄,其中最值得一提的是他在 American Medical International 的高度知名且成功的經驗。Rob 一向專注於創造股東價值;在 ICN 這短短四個半月內,他也強調同樣的紀律。
Speaking on behalf of the entire board, I can say that ICN and its shareholders will truly benefit from Rob's strategic thinking, leadership and decisive and dynamic style. Now four and a half months ago we set out with the belief that we would be bringing in a CEO from outside of the company but in four and a half short months Rob more than convinced the full board that he was the right person to take over for the following reasons which I think are important to all of our shareholders. He has demonstrated exceptional leadership in four and a half months, taking the helm at ICN during a very, very complicated period. Rob initiated and embarked on an aggressive, internal restructuring program that as you will hear today is going to yield substantial and immediate productivity and cost improvement throughout the company. Rob, working with the full board, the strategic initiative with Goldman Sachs and outside consults that has now set a new direction for the company. Maintaining the momentum that Rob has created in four and a half short months was an imperative the board set back and reflected on our new leadership direction and, of course, now Rob has recruited a world class team, which he'll speak more to in a few minutes, to take ICN forward. All of this in four and a half short months. You can see why the board of directors of ICN unanimously endorse Rob to become the permanent chairman and chief executive officer.
我代表全體董事會表示,ICN 及其股東將確實受益於 Rob 的策略思維、領導力,以及果斷且充滿動能的風格。四個半月前,我們原本相信會從公司外部延攬一位執行長;但在短短四個半月內,Rob 充分說服全體董事會,他是接任的最佳人選,原因如下,我認為這些對所有股東都很重要。他在四個半月內展現了卓越的領導力,在一段非常、非常複雜的時期接掌 ICN。Rob 發起並推動一項積極的內部重整計畫;如各位今天將聽到的,該計畫將在全公司帶來可觀且立即的生產力提升與成本改善。Rob 與全體董事會合作,並與高盛及外部顧問共同推動策略計畫,現已為公司確立新的方向。維持 Rob 在短短四個半月內所創造的動能,是董事會回顧並反思新領導方向時所設定的當務之急;當然,Rob 現在也已招募到一支世界級團隊——他將在幾分鐘後進一步說明——帶領 ICN 向前邁進。所有這些都在短短四個半月內完成。各位可以理解為何 ICN 董事會一致支持 Rob 出任永久董事長兼執行長。
As you know, the company also announced this morning the announcement, the appointment of Tim Tyson as president and chief operating officer. Tim has 25 years of health care, pharmaceutical experience with strong sales, marketing and operations background, as well as tremendous stature throughout the world in the pharmaceutical industry. Tim has both domestic and international experience with significant executive leadership experience but he's also an executive who is at home in an environment of significant change like ICN.
如各位所知,公司今天早上也宣布了這項宣布,即任命 Tim Tyson 擔任總裁兼營運長。Tim 擁有 25 年醫療保健與製藥產業經驗,具備強大的銷售、行銷與營運背景,並在全球製藥產業中享有極高聲望。Tim 兼具國內與國際經驗,擁有重要的高階領導經歷;同時,他也能適應像 ICN 這樣處於重大變革中的環境。
Tim is currently a member of GlaxoSmithKline's corporate executive team and is president of Global Manufacturing and Supply for GlaxoSmithKline where his global responsibility for supply chain manufacturing in 43 countries and all procurement operations around the world. There he has restructured the management team, reinvigorated the business, and installed a new discipline to the organization along with new and for best practices. His broad experience at GlaxoSmithKline included managing two major P&L operations, Glaxo Dermatology and Cerenex Pharmaceuticals. He also was responsible for managing all sales and marketing for the U.S. operations where he launched 32 new products, 8 of which have become blockbuster drugs. Under Tim's leadership, GlaxoSmithKline was awarded the Marketer of the Year Award from for two consecutive years.
Tim 目前是葛蘭素史克(GlaxoSmithKline)企業執行團隊成員,並擔任葛蘭素史克全球製造與供應總裁,負責其在 43 個國家的供應鏈製造,以及全球所有採購作業。在那裡,他重整了管理團隊、重振業務,並為組織導入新的紀律,同時建立新的與以推動最佳實務。Tim 在葛蘭素史克的廣泛經驗包括管理兩項主要損益(P&L)業務:Glaxo Dermatology 與 Cerenex Pharmaceuticals。他亦負責管理美國營運的所有銷售與行銷,期間推出 32 項新產品,其中 8 項成為暢銷重磅藥物。在 Tim 的領導下,葛蘭素史克連續兩年獲得頒發的「年度行銷人」獎。
I have known Tim for several years and as chairman of the search committee for ICN aggressively sought his candidacy. Tim has a successful track record with difficult restructuring situation, which is one of the many strengths that we knew would add value to the company. We are tremendously pleased to have Tim join the organization and to team with Mr. O'Leary as we move forward to create shareholder value.
我認識 Tim 已有數年,並以 ICN 遴選委員會主席身分積極爭取他參與。Tim 在艱難的重整情境中擁有成功的實績,這是我們知道能為公司增值的眾多優勢之一。我們非常高興 Tim 加入本組織,並與 O'Leary 先生攜手前進,以創造股東價值。
ICN also announced this morning the appointment of Bary Bailey as Chief Financial Officer. Bary is one of the bright financial stars in the health care industry. He has over 20 years of experience and as Executive Vice President, Pharmacy and Technology of PacifiCare Health Systems. Bary also has served as Chief Financial Officer.
ICN 今早也宣布任命 Bary Bailey 為財務長(Chief Financial Officer)。Bary 是醫療保健產業中耀眼的財務新星之一。他擁有超過 20 年經驗,並曾任 PacifiCare Health Systems 藥局與科技事業執行副總裁。Bary 亦曾擔任財務長。
At Pacific Care, Bary has provided leadership for the information technology group and for RX Solutions, the pharmacy benefit management services subsidiary of PacifiCare. Bary has a diverse background with experience in public accounting and significant roles including Vice President of Finance at American Medical International, a major for profit publicly traded hospital company. He has also served as Chief Financial Officer of a highly regarded healthcare buying consortium.
在 Pacific Care,Bary 為資訊科技團隊以及 RX Solutions 提供領導;RX Solutions 是 PacifiCare 旗下提供藥品福利管理服務的子公司。Bary 具備多元背景,曾任職於會計師事務所(public accounting),並擔任多項重要職務,包括 American Medical International(大型營利且公開上市的醫院公司)財務副總裁。他也曾擔任一家備受推崇的醫療保健採購聯盟之財務長。
Bary's had an exceptional financial career with virtually every aspect of finance in his portfolio. He also has very strong information technology background, which will bring great expertise to ICN. Bary has the added benefit of having worked with Rob for a number of years in numerous capacities. So they know each other very well.
Bary 的財務職涯極為傑出,幾乎涵蓋財務領域的各個面向。他也具備非常扎實的資訊科技背景,將為 ICN 帶來重要專業。此外,Bary 還有一項額外優勢:多年來在多種職務上與 Rob 共事。因此他們彼此非常熟悉。
It is the belief of the Board of Directors of ICN and management that the executives appointed today will provide the strength of leadership that the Company needs to guide it through the strategic restructuring, financial challenges therein and the major organizational changes that will result. I'll be happy when Rob is through to answer any questions about the decisions that have been made today. And with that, I'll turn the call back to Rob O'Leary.
ICN 董事會與管理階層相信,今日任命的高階主管將提供公司所需的領導力,帶領公司度過策略性重整、其中的財務挑戰,以及將隨之而來的重大組織變革。待 Rob 說完後,我很樂意回答各位對今日所做決策的任何問題。接下來,我把電話交回給 Rob O'Leary。
o'leary: Thanks, , you certainly set the bar high enough for the three of us. There's an awful lot there for us to live up to.
o'leary:謝謝,,你確實把我們三個人的標準訂得夠高。我們要達到的目標實在很多。
Let me underscore the Board's belief about the strength of these executives that will be joining ICN shortly. They are the kind of aggressive leaders that we need as we move forward with a new strategic vision and direction. They have strong backgrounds in pharmaceutical and the healthcare fields and they have extensive experience in restructuring situations and managing change.
我想再次強調董事會對即將加入 ICN 的這些高階主管實力的信心。在我們以新的策略願景與方向向前推進之際,他們正是我們所需要的那種積極進取的領導者。他們在製藥與醫療保健領域擁有深厚背景,並在重整情境與變革管理方面具備豐富經驗。
And they have a depth of commitment to see the organization through the successful completion of the goals we have announced today. Both Tim and Bary are making themselves available to help us through the transition period and will be here full-time on or about the first of December.
而且他們也有深度承諾,將帶領組織成功完成我們今天宣布的各項目標。Tim 與 Bary 兩位在過渡期間都願意提供協助,並將於 12 月 1 日前後全職到任。
I would like to turn your attention to a discussion of our strategic direction. Its key elements, potential growth strategies and a summary of next steps. After review of the new strategic direction, we'll move on to the quarter's performance and then close with questions and answers.
接下來我想請各位把注意力轉向我們策略方向的討論。包括其關鍵要素、潛在成長策略,以及後續步驟摘要。在檢視新的策略方向後,我們將進一步討論本季表現,最後以問答作結。
When I came onboard in June, we were faced with three sets of challenges. First, we had to focus our attention on the speciality pharmaceutical business. And set a strategic direction for those operations that would enhance shareholder value.
我在 6 月加入時,我們面臨三組挑戰。第一,我們必須把注意力聚焦在專科製藥(specialty pharmaceutical)業務。並為這些營運訂定能提升股東價值的策略方向。
Second, we needed to get ICN's overall cost structure inline with where it should be for a Company of its size and in this industry. And finally, we had to decide on an approach for our 80 percent ownership in that would maximize value for ICN shareholders.
第二,我們需要讓 ICN 的整體成本結構與其規模及所處產業應有的水準一致。最後,我們必須決定如何處理我們對持有的 80% 股權,以使 ICN 股東的價值最大化。
These, of course, are not simple challenges. Each in and of itself requires a great deal of attention and careful analysis and requires a great deal of time. You add in the four and a half months, this short period of time that we've been working, we have, I believe, made dramatic progress.
當然,這些都不是簡單的挑戰。每一項本身都需要大量關注與審慎分析,也需要投入相當多時間。再加上我們僅有四個半月這麼短的工作期間,我相信我們已取得顯著進展。
This morning we announce the adoption of a new strategic direction for ICN in which we have set forth a more focused strategy for the specialty pharma business and in which we have aggressively attacked the cost structure issue. We have also carefully analyzed several strategic options regarding our stake in and we will select among those options in the coming weeks and as we do, seek to maximize shareholder value.
今天早上我們宣布採納 ICN 的新策略方向:為專科製藥業務提出更聚焦的策略,並積極處理成本結構問題。我們也已就我們在的持股審慎分析多項策略選項,並將在未來幾週從中做出選擇;在此過程中,我們將致力於使股東價值最大化。
Our strategy in this redirection is designed to create a leaner more focused company with a strong emphasis on building shareholder value. We expect to achieve the objective through a series of steps that include restructuring the company into its core specialty pharmaceutical business, divesting those non-core businesses that do not fit the company's strategic direction and improving our overall cost structure.
此次策略轉向旨在打造一家更精實、更聚焦的公司,並強調建立股東價值。我們預期將透過一系列步驟達成此目標,包括將公司重整為以核心專科製藥業務為主、處分不符合公司策略方向的非核心業務,以及改善整體成本結構。
The restructured company will have a greater geographic and therapeutic focus while investing in a stronger product and business development capability. Specifically, we will focus on those regions with the greatest potential for growth for ICN namely North America, Latin America and Western and Central Europe. Within these geographies we also plan to strengthen our product portfolio by focusing on those therapeutic areas that have traditionally represented our strength and offer opportunities for growth such as dermatology.
重整後的公司將在地理與治療領域上更具聚焦,同時投資於更強的產品與業務開發能力。具體而言,我們將聚焦於對 ICN 最具成長潛力的地區,即北美、拉丁美洲,以及西歐與中歐。在這些地區內,我們也計畫透過聚焦於傳統上代表我們優勢且具成長機會的治療領域(例如皮膚科),來強化產品組合。
Next, as a part of our renewed focus on the core business, we have identified those business units that have few synergies and do not fit our overall strategic direction. We have already begun to take steps to divest those businesses which include our operations in Eastern Europe as well as our raw materials business in Central Europe, our business in North America and our bio-medicals operations and our unit and we are taking and have taken steps to improve our overall cost structure in our corporate and international headquarters as well as in other areas.
接著,作為我們重新聚焦核心業務的一部分,我們已辨識出那些協同效益有限且不符合整體策略方向的事業單位。我們已開始採取措施處分這些業務,包括我們在東歐的營運、在中歐的原料業務、我們在北美的業務、我們的生物醫療營運以及事業單位;同時,我們也正在並已採取措施改善公司總部與國際總部以及其他領域的整體成本結構。
We have targeted cost reductions of approximately $21 million on an annualized basis. Approximately 10 million of which have already been achieved and include the discontinuance of the company's aviation department, the closing of our Washington office and the discontinuance of associated activities, the closing down and outsourcing of the corporate PR function and the restructuring of certain corporate G&A activities.
我們鎖定的成本削減目標為年化約 2,100 萬美元。其中約 1,000 萬美元已經達成,措施包括取消公司的航空部門、關閉華盛頓辦公室並停止相關活動、關閉並外包公司公關(PR)職能,以及重整部分公司一般及行政(G&A)活動。
We anticipate further progress against this goal as we restructure other representative offices around the world and the international headquarters in Basle, Switzerland. We will keep you informed about our progress against this $21 million target.
隨著我們重整全球其他代表處以及位於瑞士巴塞爾(Basle)的國際總部,我們預期在此目標上將取得進一步進展。我們將持續向各位通報這項 2,100 萬美元目標的達成進度。
In addition to all of the above, management has also taken steps in the last four and a half months to renegotiate commitments, restructure budgets and reduce future spending which would have resulted -- which has resulted in a cost-avoidance on an annualized basis of an estimated additional $29 million. Our efforts at identifying and cost savings have not yet focused on pharmaceutical operations and the supply chain and manufacturing. We believe there are opportunities in those areas, perhaps significant opportunities, that can be addressed once the new management team is fully in place.
除上述各項之外,管理階層在過去四個半月也採取措施重新協商承諾、重整預算並降低未來支出;原本將會發生的支出——而這些措施已帶來——年化估計額外約 2,900 萬美元的成本避免(cost-avoidance)。我們在辨識與成本節省方面的努力,尚未聚焦於製藥營運以及供應鏈與製造。我們相信這些領域存在機會,甚至可能是重大機會;待新的管理團隊完全到位後即可著手處理。
As we developed our new direction, we really took a hard look at where we wanted this company to go in the next several years if it was to truly deliver value to its shareholders. We felt strongly that the focus on our core specialty pharmaceutical business is the right course of action for ICN.
在制定新方向時,我們確實嚴肅檢視了未來幾年公司應走向何處,才能真正為股東創造價值。我們堅信,聚焦於核心專科製藥業務是 ICN 正確的行動方針。
Specialty pharma has emerged as a viable and attractive model over the past decade. With a strong and sustainable outlook, the sector consists of companies with quite diversified roots. The common factor being a focus on self-marketing of products that are traditionally under the radar screen of big pharma.
專科製藥在過去十年間已成為一種可行且具吸引力的模式。在強勁且可持續的前景下,該產業由根基相當多元的公司所構成。其共同因素在於專注於自行行銷那些傳統上不在大型藥廠雷達範圍內的產品。
While market conditions are forcing the big pharma players to increasingly focus on blockbusters, this has created very attractive opportunities for a newer breed of players focused on smaller, innovative or reformulated branded products with attractive growth potential and economics. In addition, the continued mergers and focus on larger therapeutic areas have created a steady stream of attractive product acquisition opportunities.
在市場環境迫使大型藥廠業者愈來愈聚焦於重磅藥物之際,這也為一批較新型態、專注於規模較小、具創新性或重新配方之品牌產品(具備吸引人的成長潛力與經濟效益)的業者創造了非常具吸引力的機會。此外,持續的併購以及對較大型治療領域的聚焦,也帶來了穩定且具吸引力的產品收購機會來源。
ICN, at its core, has always been a specialty pharma company. Refocusing our efforts on the core business should enable us effectively to capitalize on the marketing opportunity and to deliver sustained revenue and earnings growth. By focusing on our core business, investing in the most advantageous geographic and therapeutic areas and improving our overall cost structure, we are establishing a strong platform from which ICN can achieve desirable future growth.
ICN 從本質上一直都是一家專科製藥公司。將我們的努力重新聚焦於核心業務,應能使我們有效把握行銷機會,並實現持續的營收與獲利成長。透過聚焦核心業務、投資於最具優勢的地理市場與治療領域,並改善整體成本結構,我們正在建立一個強健的平台,使 ICN 能夠達成理想的未來成長。
Our strategy to drive growth over the next several years involves the following steps. First, we look to evolve the U.S. business into a leading dermatology company. We selected product acquisitions and end licensing of delivery technologies while building a pipeline of newly formulated and innovative products over time.
我們在未來數年推動成長的策略包含以下步驟。第一,我們希望將美國業務發展為領先的皮膚科公司。我們透過選擇性的產品收購與導入(end licensing)給藥技術,同時隨時間建立新配方與創新產品的產品線(pipeline)。
Second, we plan to fully capture the potential of our Latin American region, building on our strength in Mexico to help drive growth. Our plans for this market involves continued product acquisitions, emphasizing on existing development and reformulation capabilities and expanding the sales force within Latin America.
第二,我們計畫充分掌握拉丁美洲地區的潛力,並以我們在墨西哥的優勢為基礎來推動成長。我們對該市場的計畫包括持續進行產品收購、強調既有的開發與重新配方能力,並擴大拉丁美洲的銷售團隊。
Third, we seek to evolve our pharmaceutical business in Western and Central Europe with a particular emphasis on Germany, Italy and Poland, into a more focused business with greater attention paid on a few therapeutic areas. In this renewed focus, we will utilize selected acquisitions to build critical scale in certain markets and expand the product portfolio. We believe we are on a strong track record for success.
第三,我們希望將西歐與中歐的製藥業務(特別著重於德國、義大利與波蘭)發展為更聚焦的業務,並將更多注意力放在少數幾個治療領域。在此重新聚焦之下,我們將運用選擇性的收購,在特定市場建立關鍵規模並擴充產品組合。我們相信我們正走在成功的強勁軌道上。
We know the months ahead will be intense, as we further our progress and complete our restructuring. We expect that the divestitures will be completed over the next six to 12 months while the broader restructuring initiatives such as the manufacturing and supply chain overhauls, will take longer.
我們知道接下來的幾個月將會非常緊湊,因為我們將進一步推進進度並完成重整。我們預期資產處分將在未來 6 到 12 個月內完成,而更廣泛的重整措施(例如製造與供應鏈的全面改造)則需要更長時間。
Now I'd like to turn your attention, if I may, to the third quarter results that we announced this morning. As reported, revenues from continuing operations for the third quarter 2002 were $215.9 million as compared with revenues of 182.4 million in the same period last year. An 18 percent increase.
現在,如果可以的話,我想請各位把注意力轉向我們今天早上公布的第三季業績。如所報告,2002 年第三季持續營運的營收為 2.159 億美元,相較去年同期的 1.824 億美元。成長 18%。
On a GAP basis, we reported a net loss including a non-reoccurring unusual and extraordinary items for the quarter of 74.9 million or 90 cents per diluted share, compared with 11.7 million or 14 cents per diluted share in the same period last year. As you would expect, from any company that is in the midst of great change, and on the cusp of a new strategic direction, the financial results for the third quarter contain a number of unusual items.
按 GAP 基礎計算,我們本季報告的淨損包含一次性、非經常性的異常與非常項目,為 7,490 萬美元,或稀釋後每股 0.90 美元;相較去年同期為 1,170 萬美元,或稀釋後每股 0.14 美元。如各位所預期,任何正處於重大變革之中、且站在新策略方向門檻上的公司,其第三季財務結果都會包含若干異常項目。
I hope to put those items in the proper context for you today. First, primarily as a result of steps taken in the strategic restructuring, the company reported several non-reoccurring and unusual items in the third quarter. Normally occurring and unusual charges in the third quarter totaled 104.6 million or 65.8 million after taxes or 79 cents per diluted share which primarily included impairment charges recorded on certain assets, severance costs, flood damage to the company's business in the Czech Republic and environmental costs. We have detailed non-reoccurring and unusual charges in Table 2 and Table 3 attached to the press release. You'll find them at the bottom of both of those tables. Although we believe the bulk of the non-reoccurring and usual charges are behind us, it is possible that we would incur additional charges in the fourth quarter.
我希望今天能將這些項目放在適當的脈絡中為各位說明。首先,主要由於策略性重整所採取的步驟,公司在第三季認列了數項非經常性與異常項目。第三季的非經常性與異常費用合計 1.046 億美元;稅後為 6,580 萬美元,或稀釋後每股 0.79 美元,主要包括對特定資產所認列的減損費用、資遣成本、公司在捷克共和國業務遭受的洪災損失,以及環境成本。我們已在新聞稿所附的表 2 與表 3 中詳列非經常性與異常費用。您可在這兩個表格的底部找到相關內容。雖然我們相信大部分的非經常性與異常費用已經過去,但第四季仍可能發生額外費用。
That , as I mentioned earlier, we have -- intend to several operations and businesses of the company for divestiture that do not fit the company's new strategic direction. Those operations that are further along in the process, namely and our unit, have been segregated in our financial statement as discontinued operations. Accounting rules, of course, require that we remove the income and expense from these businesses from our ongoing or continuing operations and report them as a single line item, net of income tax expense in the income statement and we must restate prior periods so that we have comparability in our reporting. A net loss from these discontinued operations in the current quarter were 34.5 million or 41 cents per share. Included in that loss is an impairment charge on these operations to appropriately value them at fair value of 31.6 million. These operations -- those operations that were not far enough along in the process of divestiture to qualify for discontinued operations treatment, namely eastern Europe, our raw materials business in central Europe and the Biomedical unit, have been continued -- reported in continuing operations in the current quarter. We expect to report them as discontinued in the 2002 fourth quarter. An impairment charge of 74.6 million on these operations was included in the non-reoccurring and unusual items in the current period. In order to foster a level of transparency and to give you a basis for thinking about the financials for our ongoing continuing operations, we have attached a pro forma tables to the press release which treats all of these operations to be divested as if they were discontinued in the current period. Table 3, which is attached to the release, presents this information for you.
至於那, 如我先前提到的,我們已經——打算將公司若干不符合新策略方向的營運與業務列為處分對象。在處分流程中進展較快的那些營運,亦即以及我們的單位,已在財務報表中列為停業單位。當然,會計準則要求我們將這些業務的收入與費用自我們的持續營運中移除,並在損益表中以單一科目(扣除所得稅費用後)呈列;同時我們必須重編前期數字,以確保報導具可比性。本季停業單位的淨損為 3,450 萬美元,或每股 0.41 美元。該損失包含對這些營運所認列的減損費用 3,160 萬美元,以適當將其估值至公允價值。這些營運——亦即尚未在處分流程中進展到足以符合停業單位認列條件的營運,包括東歐、我們在中歐的原料業務以及 Biomedical 單位——在本季仍——列於持續營運中報告。我們預期在 2002 年第四季將其列為停業單位。對這些營運所認列的減損費用 7,460 萬美元,已包含在本期的非經常性與異常項目中。為了提升透明度,並提供各位思考我們持續營運財務表現的基礎,我們在新聞稿中附上了備考(pro forma)表格,將所有這些擬處分的營運視同在本期即已列為停業單位。隨新聞稿附上的表 3 為各位呈現了這些資訊。
Finally, we reported an extraordinary gain, net of taxes, in the third quarter of 10.9 million from the purchase -- repurchase of ICN 6 ½ percent convertible, subordinated notes in open market transactions. So while these unusual items had an impact on third quarter results, they were nearly all driven by our decision to reposition the company for future growth opportunities. When you remove the non-reoccurring, unusual and extraordinary items, we reported net income from continuing operations in the third quarter of 15.1 million or 18 cents per diluted share and operating income before non-reoccurring and unusual items was 35.9 million in the third quarter or a 26 percent increase over a comparable period last year. The improvement in ICN's results reflected the strong performance by Ribapharm which reported their earnings two days ago. The improvement at Ribapharm was driven by higher royalties, which reflects increased sales of ribavirin by Schering Corporation. The specialty pharmaceuticals business, however, turned in a mixed performance with some strength in Latin America offset by a decrease in revenues for our North American operations. Our North American revenues declined 13.6 million or 45 percent. The decline in sales in part reflects the impact of the company's continuant program to reduce inventories at its U.S. wholesaler and the company's decision to reduce shipments of its Mestinon products in anticipation of the possibility of generic competition. @@@@@@@@@@@@@@ o'leary: ... at its U.S. wholesalers. And the Company's decision to reduce shipments of its Mestinon products in anticipation of the possibility of generic competition.
最後,我們在第三季認列了一項非常利益(扣稅後)1,090 萬美元,來自於在公開市場交易中購買——回購 ICN 6 ½% 可轉換次順位票據。因此,雖然這些異常項目對第三季結果造成影響,但幾乎全都是由我們為了重新定位公司、以把握未來成長機會的決策所驅動。剔除非經常性、異常與非常項目後,我們第三季持續營運的淨利為 1,510 萬美元,或稀釋後每股 0.18 美元;而剔除非經常性與異常項目前的營業利益為 3,590 萬美元,較去年同期可比期間成長 26%。ICN 業績的改善反映了 Ribapharm 的強勁表現,該公司已於兩天前公布其獲利。Ribapharm 的改善主要由較高的權利金所帶動,反映 Schering Corporation 的利巴韋林(ribavirin)銷售增加。然而,專科製藥業務表現好壞參半:拉丁美洲的部分強勁,但被北美營運營收下滑所抵銷。我們北美營收下降 1,360 萬美元,或 45%。銷售下滑部分反映公司持續推動的計畫,以降低其美國批發商的庫存,以及公司因預期可能出現學名藥競爭而決定減少 Mestinon 產品出貨的影響。 @@@@@@@@@@@@@@ o'leary: ... at its U.S. wholesalers.以及公司因預期可能出現學名藥競爭而決定減少 Mestinon 產品出貨。
The wholesaler inventory reduction program is expected to continue well into 2003. Latin American sales totaled 32 million in the 2002 third quarter compared with 30.7 million a year ago. A four percent increase in spite of an aggregate 17 percent devaluation of currencies in the region.
批發商庫存降低計畫預期將持續到 2003 年相當一段時間。2002 年第三季拉丁美洲銷售額合計 3,200 萬美元,較一年前的 3,070 萬美元增加。儘管該地區貨幣合計貶值 17%,仍成長 4%。
Operating income was 11.2 million compared with eight million a year ago, up 40 percent. Results of the third quarter benefitted from the strong sales of and Virazole, which increased to 9.1 million in the 2002 third quarter from 7.9 million in the third quarter of 2001.
營業利益為 1,120 萬,較去年同期的 800 萬增加 40%。第三季的業績受惠於與 Virazole 的強勁銷售,該等產品銷售額由 2001 年第三季的 790 萬增加至 2002 年第三季的 910 萬。
Sales in Western Europe, which includes Central Europe, totaled 49 million in the third quarter of 2002, an increase of three percent compared with the same period last year. The region reported an operating loss of 5.1 million compared with an operating profit of 6.8 million in the same period last year. Western Europe benefitted from new products we acquired in the past several quarters and introduced into the Italian and German market.
2002 年第三季西歐(包含中歐)銷售額合計 4,900 萬,較去年同期增加 3%。該地區營業損失為 510 萬,去年同期則為營業利益 680 萬。西歐受惠於我們在過去數季收購的新產品,並已導入義大利與德國市場。
This was offset at the operating income line by the flood damage we sustained to our business in the Czech Republic. As I indicated earlier, the raw materials business is in the process of debt . Eastern European sales in the third quarter of 2002 were 22.9 million. Unchanged from the third quarter of 2001. The Eastern European region reported an operating loss of 75.7 million compared with a $1.5 million in the third quarter of 2001.
然而,在營業利益層面,這些成果被我們在捷克共和國業務所遭受的洪災損害所抵銷。如我先前所述,原料業務正處於債務的過程中。
The increased operating loss was primarily due to the impairment charge of 73.1 million related to the of this business. Sales in Asia, Australia and Africa in the 2002 third quarter were 15.2 million compared with 12.5 million in the same period last year. An increase of 21 percent. The region posted an operating loss of 2.3 million compared with a 1.2 million a year earlier.
營業損失增加主要係因與該業務相關的 7,310 萬減損費用。2002 年第三季亞洲、澳洲及非洲的銷售額為 1,520 萬,去年同期為 1,250 萬。增加 21%。該地區營業損失為 230 萬,去年同期為 120 萬。
Results in the third quarter reflected strong sales of and in the Far East. At the operating income line this was offset by writeoffs in the third quarter for certain inventory receivables as well as costs associated with a joint venture in China.
第三季的結果反映出遠東地區與的強勁銷售。但在營業利益層面,第三季針對部分存貨應收款項的沖銷,以及與中國合資企業相關的成本,抵銷了上述成果。
Before we close, I'd like to spend a few minutes discussing certain balance sheet components. First, cash at the end of September totaled 244 million, which was an $83 million decline from the balance at the end of 2001 and a decline of 37 million during the quarter. Royalty cash inflows in the quarter -- 61 million -- were more than offset by cash outflows that primarily included payments for subordinated note repurchases -- 40 million, and stock option purchases -- 24 million, interest and dividends -- 24 million, and legal and other net of 11 million.
在結束之前,我想花幾分鐘討論資產負債表的若干組成項目。首先,9 月底現金合計 2.44 億,較 2001 年底餘額減少 8,300 萬,且本季減少 3,700 萬。本季權利金現金流入為 6,100 萬,但被現金流出所抵銷;流出主要包括次順位票據回購付款 4,000 萬、股票選擇權購買 2,400 萬、利息與股利 2,400 萬,以及法律及其他淨1,100 萬。
We believe that the Company has sufficient cash resources to meet our ongoing operating needs. Accounts receivable on September 30th totaled 230 million, down 33 million from the balance at December 31, 2001. Inventory at September 30 was down as well totaling 157 million. Stockholders' equity decreased by 32 in the year to 779 million at the end of September.
我們相信公司擁有足夠的現金資源以滿足持續營運需求。截至 9 月 30 日,應收帳款合計 2.30 億,較 2001 年 12 月 31 日餘額減少 3,300 萬。截至 9 月 30 日,存貨亦下降,合計 1.57 億。股東權益於本年度減少 32,至 9 月底為 7.79 億。
The remainder of 2002 will be one of continued focus on executing the strategic direction and rounding out the management team. As the new management team begins to develop our action plans, we will be in a better position to give guidance for 2003. We have every reason to believe, however, that our efforts will ultimately drive double-digit top and bottom line growth.
2002 年剩餘期間將持續聚焦於落實策略方向並補齊管理團隊。隨著新管理團隊開始制定行動計畫,我們將更有條件提供 2003 年的指引。然而,我們完全有理由相信,我們的努力最終將帶動營收與獲利(上、下線)雙位數成長。
We've covered an immense amount of ground on the call today. Before we close the presentation, I want to leave you with a perspective on what we've accomplished and where we see ourselves going in the next few months.
今天的電話會議我們涵蓋了非常多的內容。在結束簡報之前,我想讓各位了解我們已完成的成果,以及我們在未來幾個月的前進方向。
I view our activities as a six-step process. At least three of which we have almost fully completed and the fourth we have made significant progress on in today's announcement. The last two steps will be developed when our new management team is fully in place. Let me detail them for you.
我將我們的活動視為六個步驟的流程。其中至少三個我們幾乎已完全完成,而第四個我們也在今天的公告中取得了重大進展。最後兩個步驟將在新管理團隊完全到位後制定。我來為各位詳細說明。
First, and most importantly, we have stopped doing things that simply do not deliver value. Second, we have significantly reduced the company's overall infrastructure costs. Third, we have established a sense of direction for the specialty pharmaceutical business that will add value. Fourth, we have added strong depth to the management team in the new executives announced today and we expect to round out that team in the months ahead. Fifth, we expect to improve our ability to execute as a company in the areas of product lifecycle management, in licensing of new products in a more focused way, improving our ability to market and deliver products and streamlining our supply chain and manufacturing capabilities.
第一,也是最重要的,我們已停止做那些根本無法創造價值的事情。第二,我們已大幅降低公司的整體基礎架構成本。第三,我們已為專科藥品業務建立一個能夠增值的方向感。第四,我們透過今天宣布的新任高階主管,為管理團隊增添了強而有力的深度,並預期在未來幾個月補齊該團隊。第五,我們預期將提升公司在產品生命週期管理、以更聚焦方式引進授權新產品、提升行銷與交付產品的能力,以及精簡供應鏈與製造能力等方面的執行力。
These simply are things that are about blocking and tackling as a specialty pharmaceutical business and we intend to focus on them. Sixth, and finally, we plan to grow the business in ways that are attractive and add value to the organization and to shareholders.
這些事情本質上就是專科藥品業務的基本功,我們打算聚焦於此。第六,也是最後,我們計畫以具吸引力且能為組織與股東創造價值的方式來成長業務。
We're excited about the prospects for the new ICN Pharmaceuticals. With a new management team in place and a new strategic direction that will provide a stronger platform for growth, we believe that ICN will be a leaner, more focused company in the future with a top priority on building value for shareholders.
我們對全新的 ICN Pharmaceuticals 的前景感到振奮。在新管理團隊到位,以及能提供更強成長平台的新策略方向之下,我們相信 ICN 未來將成為更精實、更聚焦的公司,並以為股東創造價值作為最優先事項。
And with that, I'd like to open the call up for questions and just remind everyone, if we could, that please one question to a questioner and then we will recycle the people after everyone who wishes to ask a question has had an opportunity.
接下來,我想開放電話會議進行提問,並提醒各位:若可以的話,請每位提問者先問一個問題,待所有想提問的人都有機會之後,我們再回到先前的人繼續提問。
Operator, if you would, may we please now have the first question.
接線員,麻煩現在請提供第一個問題。
Operator
Operator
Sure, the question and answer session will be conducted electronically today. If you would like to ask a question, simply press the * key followed by the digit 1 on your touchtone telephone. We'll proceed in the order that you signal us and take as many questions as time permits.
好的,今天的問答環節將以電子方式進行。若您想提問,請在您的按鍵式電話上按下 * 鍵後再按數字 1。我們將依您發出訊號的順序進行,並在時間允許下盡可能回答更多問題。
Once again, if you would like to ask a question press *1 at this time and we'll first hear from Michael Tung of Walkovia Securities.
再次提醒,若您想提問,請此刻按下 *1。首先我們將聽取 Walkovia Securities 的 Michael Tung 的提問。
Hi, good morning. Thanks for taking the question. A little bit more strategically, you've talked about how you're focusing in terms of the specialty pharmaceutical business into different therapeutic categories, can you talk a little bit more about that other than dermatology which areas are you looking at and how do you expect to structure the sales and marketing infrastructure around those therapeutic categories? Do you expect to have separate sales forces and what's, may be a little premature at this point, but the respective sizes of such sales forces?
嗨,早安。謝謝讓我提問。從策略面再多問一點:你們談到在專科藥品業務方面,會聚焦於不同的治療領域;除了皮膚科之外,能否再談談你們還在看哪些領域?以及你們預期將如何圍繞這些治療領域來建構銷售與行銷的基礎架構?你們是否預期會有不同的銷售團隊?以及(也許現在問有點太早)各銷售團隊大致的規模會是多大?
Unidentified
Unidentified
Well, Michael, this, again, is Rob. You're -- you perhaps have anticipated the response here. I think it is just a bit premature. We're certain of the dermatology focus in North America and, obviously, we will continue to focus on a variety of anti-infectives, but I think the -- the exact therapeutics focus and -- and the organization of the sales force are going to be left to Tim's arrival. We've done an awful lot of good groundwork done on those issues, but the actual decisions will be cut as the new management team gets on board and I can assure you that particularly Mr. Tyson's case, he has superb experience in these areas and will be very, very focused on them early on.
Michael,我再說一次,我是 Rob。你——你可能已經預期到這個回覆。我認為現在確實還稍微早了一點。我們很確定北美會聚焦於皮膚科,當然我們也會持續聚焦於多種抗感染產品;但我認為——具體的治療領域聚焦以及——以及銷售團隊的組織方式,將留待 Tim 到任後再決定。我們已在這些議題上做了大量且扎實的前期準備,但實際決策將在新管理團隊到位後拍板;我可以向你保證,尤其是 Tyson 先生,他在這些領域擁有極佳的經驗,並會在早期就非常、非常專注於此。
OK. A quick follow up, if I may, when do you expect - or when should we expect to hear results from that, I guess, planning over the next several months?
好的。如果可以的話,我再快速追問:你們預期——或我們應該預期——何時會聽到接下來幾個月(我想是)規劃的結果?
Unidentified
Unidentified
We're going to be - that very subject as well as the ability to give you some sense of 2003 - we hope to be back to you early in 2003. By that, I'm hopeful that it will be January and to give you a real sense of where we're going and how those plans are going to roll out. What sort of milestones we have in mind, and the processes that we're building or reinforcing to deliver on those.
我們將會——就這個主題以及我們提供 2003 年展望的能力——希望在 2003 年初回覆各位。我希望會是在 1 月,讓各位清楚了解我們要往哪裡走,以及這些計畫將如何展開。我們心中有哪些里程碑,以及我們正在建立或強化哪些流程來確保交付成果。
My plan, although I don't want you to hold to me this specifically, that , myself and the management get on the road to sit down with a number of you sometime very, very early in 2003 and begin to fill in these blanks.
我的計畫是——雖然我不希望你把我特別綁死在這一點上——我本人以及管理團隊會在2003年非常、非常早的時候,找個時間與你們當中的幾位上路坐下來談,並開始把這些空白補齊。
Great. Thank you very much.
很好。非常感謝。
Unidentified
Unidentified
Thank you, .
謝謝,.
Operator
Operator
Our next question comes from Larry Smith of Gerard Klauer.
下一個問題來自Gerard Klauer的Larry Smith。
Yes. Could you tell us what the options are for that could be considered?
是的。您能否告訴我們可能被考慮的選項有哪些?
Unidentified
Unidentified
Well, there are - I'm sure there are numerous options, but the obvious overview options are, one, to continue with the spin out. Two, to leave it as it is and third, to buy it in. There are a number of permutations of all of those things, of course.
嗯,選項——我相信有很多選項,但顯而易見的概括性選項是:第一,繼續進行分拆。第二,維持現狀。第三,把它買回來。當然,這些做法各自都有許多不同的組合與變形。
But we're not prepared to elaborate any further than that at this point.
但在目前這個時間點,我們不準備再進一步闡述。
Could you just tell us when that decision might be made?
您能否簡單說一下大概何時會做出決定?
Unidentified
Unidentified
I expect it to be made certainly by the end of the year and hopefully in the weeks immediately ahead.
我預期肯定會在年底前做出決定,並希望就在接下來的幾週內。
OK. Thank you.
好的。謝謝。
Operator
Operator
Our next question comes from of Iridium Assets.
下一個問題來自Iridium Assets的。
Good morning Rob, Randy.
早安,Rob、Randy。
Unidentified
Unidentified
Good morning .
早安,.
Want to take the opportunity to - want to thank you, both of you, for - I don't know that people really have an appreciation of just how difficult your task has been and how much effort you have expounded on behalf of the shareholders of this company.
我想藉這個機會——想要感謝你們兩位——我不確定大家是否真的理解你們的任務有多麼困難,以及你們為了本公司股東付出了多少努力。
And so I would like to just express my personal appreciation for having gotten you involved in an extraordinarily difficult restructuring and management task. So again, I think that people should have a profound appreciation for - and I understand its very hard for them to understand just how difficult this process has been and how demanding it has been.
因此,我想表達我個人的感謝,感謝你們投入到一項極其艱難的重整與管理任務中。所以再次強調,我認為大家應該對此有深刻的感激——而我也理解,他們很難真正明白這個過程究竟有多困難、要求有多高。
As you might expect for me to ask, will there be any changes on the board? Will the new president be offered a board seat and, I guess, as a major holder this point given that your permanent appointment now is Chairman and CEO and maybe Randy as independent director might want to address this. Is the board prepared to publicly make it's request given - in light of all we've seen in corporate governance to make a stand and request that resign himself from the board of this company?
如你所料我會問:董事會會有任何變動嗎?新任總裁是否會獲提供董事席位?另外,我想,鑑於你現在已被正式任命為董事長兼執行長,而Randy作為獨立董事也許可以回應這點——鑑於我們在公司治理方面所見的一切,董事會是否準備公開表態並提出要求,請自行辭去本公司董事職務?
Unidentified
Unidentified
Randy, did you want to take that?
Randy,你要回答這個嗎?
- Chairman of the Board, Viasys
- Chairman of the Board, Viasys
Sure. And , speaking personally, your comments about the work that has been accomplished in four and a half short months mean a lot. I think that in many ways you deserve the credit for the initiative that has lead to what I think is a extraordinary new future for the company.
當然。而且,就我個人而言,你對於在短短四個半月內所完成工作的評論,對我意義重大。我認為在很多方面,你應該為這項倡議獲得肯定;正是這項倡議帶來了我認為公司非凡的新未來。
You asked a couple of questions. With regard to Tim Tyson joining the board, you know, corporate governance being so much in the forefront of corporate America these days, the overwhelming preference of shareholders is to only have one insider on the board. That, obviously, now will be Rob O'Leary as chairman and CEO. Tim Tyson won't be joining the board immediately. Tim was brought on with the view that in the years to come he would be a successor to Rob and it would probably be an appropriate time to put him on the board at that point in time. With regard to Mr. Panic's remaining on the board, Milan has been steadfast in his results that he will not step down from the board of directors and, you know, despite the enormous amount of controversy surrounding Mr. Panic, there have been many instances where he has cooperated in this entire process, cooperated in the change that lead to Mr. O'Leary named permanent chairman and chief executive officer, as well as Mr. Tyson and Mr. Bailey coming in and with regard to his continuance on the board, his term expires this year and it is probably not the intention of the other directors that he would continue beyond his current term and I think Mr. Panic probably has other plans that will take him in different directions as well. That term, if I'm correct Rob and , expires in the April/May time frame.
你問了幾個問題。關於Tim Tyson加入董事會,你知道,近來公司治理在美國企業界成為焦點,股東的壓倒性偏好是董事會只保留一位內部人士。顯然,現在這位將是擔任董事長兼執行長的Rob O'Leary。Tim Tyson不會立即加入董事會。聘任Tim時的考量是,未來幾年他將成為Rob的接班人,而在那個時間點讓他進入董事會可能更為合適。至於Panic先生是否繼續留任董事會,Milan一直堅持他的立場:他不會從董事會辭任。你知道,儘管Panic先生周遭存在大量爭議,但在整個過程中他在許多方面確實有配合,包括配合推動變革,使O'Leary先生被任命為永久董事長兼執行長,以及Tyson先生與Bailey先生的加入。至於他是否繼續留任董事會,他的任期將於今年屆滿,其他董事很可能無意讓他在本屆任期之後繼續留任;而我想Panic先生自己也可能另有規劃,將朝不同方向發展。如果我沒記錯,Rob和,該任期是在4月/5月左右到期。
Unidentified
Unidentified
That's correct, .
沒錯,.
David, I would be remiss if I didn't add my thanks for your kind comments and your leadership in this . It's very much appreciated. Let me -- it's -- this has been a major challenge and there are an awful lot of good people here at ICN who have -- who operate below the radar screen and have done some really wonderful things in this period and the results we announced this morning wouldn't be possible without their efforts.
David,如果我不補上一句感謝你友善的評論以及你在這中的領導,我就太失禮了。我們非常感激。我再補充——這是一項重大挑戰,而ICN這裡有許多優秀的人才——他們在雷達下默默運作——在這段期間做了很多非常出色的事情;我們今天早上公布的成果,若沒有他們的努力是不可能達成的。
, again, I'd like to just again thank you both for having seen this company through this extraordinary difficult time and to kind of let you know other shareholders that is enormously supportive of Rob's appointment and and the rest of the board's continuing support of Rob's efforts. So, that being said, why don't we go -- move on.
,再次,我也想再一次感謝你們兩位帶領公司度過這段極其艱難的時期,並讓你們知道其他股東,對Rob的任命給予極大的支持,以及董事會其他成員也持續支持Rob的努力。話說到這裡,我們就——繼續往下進行吧。
Unidentified
Unidentified
Thank you.
謝謝。
Operator
Operator
Our next question comes from , .
下一個問題來自,.
Hi. Could you outline what the revenue would be without the discontinued operations and do you expect more charges in Q4 or do you have the kind of discontinued operations now at what you think is realizable value?
嗨。你能否概述一下,若不包含已終止營運,營收會是多少?另外,你預期第四季還會有更多費用/一次性損失嗎?或者你們目前對已終止營運的估值,已經是你們認為可實現的價值?
Unidentified
Unidentified
Yeah, with -- this is @@@@@@@@@@@@ unid: ... have that could have discontinued operations now at what you think is realizable value.
是的,這是@@@@@@@@@@@@ unid: ... 你們現在是否已將已終止營運按你們認為可實現的價值入帳?
Unidentified
Unidentified
Yes, this is still low, , with regards to the revenue. That number would come down approximately 45 million if you were to subtract the discontinued for the quarter and then the to be discontinued that we expect to take action on in the fourth quarter.
是的,,就營收而言仍然偏低。如果你把本季的已終止營運,以及我們預期在第四季採取行動、將要終止的部分扣除,該數字大約會減少4,500萬。
Unidentified
Unidentified
OK. And that was 45 million in Q3 '02. How about Q3 '01 just for comparison's sake. Or Q2 or something.
好的。也就是2002年第三季是4,500萬。那2001年第三季呢,作為比較?或者第二季之類的。
Unidentified
Unidentified
That would be approximately the same amount.
大約也是同樣的金額。
Unidentified
Unidentified
OK.
好的。
Unidentified
Unidentified
On a run rate basis.
以運行率(run rate)來看。
Unidentified
Unidentified
And charges in Q4?
那第四季的費用/一次性損失呢?
o'leary: , I think we're going to stick with our statement in the script that we think we've got the great bulk of the charges behind us. But it is possible there will be some additional charges in the fourth quarter. We're not prepared to rule that out at this point.
o'leary:,我想我們會維持講稿中的說法:我們認為大部分的費用/一次性損失已經在我們身後了。但第四季仍有可能會有一些額外費用。目前我們不準備排除這種可能性。
Unidentified
Unidentified
OK. And how long do you think it takes to dispose of all the discontinued Ops?
好的。那你認為處分所有已終止營運需要多久?
o'leary: Oh, I don't have my crystal ball with me today. I can only tell you that we are off to a running start and very actively marketing most of these now. And, you know, some of these are going to be a challenge. There's no question because we're going to insist on full value.
o'leary: 噢,我今天沒帶水晶球。我只能告訴你,我們已經有了很好的起步,並且正非常積極地行銷其中大部分資產。而且,你知道,其中一些會是個挑戰。毫無疑問,因為我們會堅持取得足額價值。
So we're saying somewhere in the six month to one year time frame. In the meantime, if I may branch from your question, , because it begs the question, if you're going to have them in the operation for -- even though they're listed as discontinued they need to be managed aggressively in the meantime.
所以我們的說法是,大約在六個月到一年的時間範圍內。同時,如果我可以從你的問題延伸一下,,因為這也引出另一個問題:如果在這段期間它們仍在營運中——即使被列為已終止營運——在此期間也必須積極管理。
And the cost reductions that I reported to you earlier, some of them have been in the discontinued operations. And some of the -- there will be additional cost reductions in the discontinued operations as we attempt to lean them up and make them more valuable as we go forward. So we will continue to manage them aggressively through the sale period.
而我先前向你報告的成本削減,有一部分就發生在已終止營運中。並且,隨著我們嘗試讓它們更精實、在未來更具價值,已終止營運中還會有進一步的成本削減。因此,在出售期間我們將持續積極管理它們。
Unidentified
Unidentified
OK, great. And could you ask Bary to see if he could put out the balance sheet with the income statement when he joins?
好的,很好。另外,你能不能請 Bary 在他加入時,看看是否可以把資產負債表和損益表一起提供?
o'leary: I'd be happy to pass that on. I think I see a bunch of people making that note right now.
o'leary:我很樂意轉達。我想我現在看到有一群人正在記下這點。
Unidentified
Unidentified
Thank you.
謝謝。
o'leary: All right. operator: Next we'll hear from of UBS Warburg.
o'leary:好的。 operator:接下來我們將聽取UBS Warburg 的提問。
o'leary: Andrew, yes?
o'leary:Andrew,是你嗎?
Yes, Hi. Thank you. Just a couple of question and obviously Ribapharm from my perspective. What are some -- if you wouldn't mind maybe elaborating a little bit more if you can -- what are maybe some of the variables that you're considering that will lead you to, you know, a good decision as to pursue one of the options that you outlined earlier from the previous questions?
是的,嗨。謝謝。我只有幾個問題,當然是從我對 Ribapharm 的角度來看。有哪些——如果你不介意、也許可以再多闡述一點——你們正在考量的一些變數,會引導你們做出一個好的決定,去採取你先前在前面問題中提到的某個選項?
In terms of whether you'd spinoff, keep it the same or buy it back. I guess, what are the key sort of, you know, lightening rods or key issues that you're looking at and evaluating that will help you reach a decision in a couple of weeks?
就是否要分拆、維持現狀或買回而言。我想問的是,你們正在關注並評估的關鍵「引爆點」或關鍵議題是什麼,能幫助你們在幾週內做出決定?
o'leary: , elaboration isn't going to be really possible at this juncture. We're evaluating our options with respect to Ribapharm -- our 80 percent holding in Ribapharm. And any decisions we make will be done with an eye toward maximizing shareholder value. Any discussion about those options or their financial ramifications would be absolutely premature at this time.
o'leary:,在這個時間點,恐怕不太可能再做更進一步的說明。我們正在評估與 Ribapharm——也就是我們持有 Ribapharm 80% 股權——相關的各種選項。我們所做的任何決策,都會以極大化股東價值為出發點。此時討論這些選項或其財務影響,絕對為時過早。
Is keeping it in the current situation an option?
維持目前的狀況也是一個選項嗎?
o'leary: Everything is on the table.
o'leary:所有選項都在考量範圍內。
OK, thank you.
好的,謝謝。
Operator
Operator
As a reminder, if you would like to ask a question, press star one at this time. And we'll now hear from of Franklin Street Partners.
提醒各位,如欲提問,請此刻按星號 1。接下來我們將聽取Franklin Street Partners 的提問。
Thank you. I have two questions. One, could you just explain the compensation packages being offered to the new management team in terms of options, salary and have a cash bonus, if anything is determined? And, secondly, if one eliminates the royalty revenue line from the income statement is it a goal of this current restructuring to make the company profitable without that line on the income statement and when might that be?
謝謝。我有兩個問題。第一,能否就提供給新管理團隊的薪酬方案做個說明,包括選擇權、薪資,以及是否有現金獎金(若有的話,如何決定)?第二,如果把損益表中的權利金收入那一行剔除,這次重整的目標是否是在沒有那一行收入的情況下讓公司獲利?大概何時能達成?
- Chairman of the Board, Viasys
- Chairman of the Board, Viasys
Well, this is Randy, would you like me to handle the first part?
嗯,我是 Randy,你希望我來回答第一部分嗎?
Sure, why don't you Randy.
當然,Randy,你來回答吧。
- Chairman of the Board, Viasys
- Chairman of the Board, Viasys
Okay, with regard to -- with regard to the compensations, this is Randy Thurman, I'm also chairman of the ICN Compensation Committee of the board of directors.
好的,關於——關於薪酬部分,我是 Randy Thurman,我同時也是 ICN 董事會薪酬委員會主席。
Two background statements before I give you any specifics. The Board and the Compensation Committee retain the services of TPF&C as well as the judgment of the search firm that we employed to -- to support the activity of bringing in the new executives and the competitive salaries for the position of Chairman and CEO, President and COO and Chief Financial Officer were all -- that competitive data was provided to us by , TPF&C as well as the involved search firm.
在我提供任何具體內容之前,先做兩點背景說明。董事會與薪酬委員會聘請了 TPF&C 的服務,也參考了我們所聘用的獵才公司之判斷——以支持延攬新高階主管的工作;而董事長兼執行長、總裁兼營運長以及財務長等職位的具競爭力薪資水準——這些競爭性資料是由、TPF&C 以及相關獵才公司提供給我們的。
The compensation numbers, of course, will all be made public as a result of the company's filings. The base pay for both -- for Mr. O'Leary, Mr. Thiessen and Mr. Bailey are all within the competitive range of what's called the TPF&C Pharmaceutical Executive Database which also size adjust using regression analysis for the -- the size of ICN compared to the other pharmaceutical companies.
當然,所有薪酬數字都會因公司申報文件而公開。O'Leary 先生、Thiessen 先生與 Bailey 先生的基本薪資,皆落在所謂 TPF&C 製藥業高階主管資料庫(TPF&C Pharmaceutical Executive Database)的競爭區間內;該資料庫也會透過迴歸分析,依 ICN 相較其他製藥公司的規模進行調整。
Each of their base pays are within the -- the range between the -- you know, the minimum and the max and -- and, at least, in a couple of cases, tends slightly toward the lower end of that range.
他們每位的基本薪資都在——你知道的——最低到最高的區間之內;而且至少在幾個案例中,還略偏向該區間的較低端。
Each of these individuals will be on an annual bonus that will be 100 percent tied to objectives that will be agreed to by the Board of Directors. Those objectives are all going to be geared toward specific goals that drive shareholder value.
這些人士每位都會有年度獎金,其 100% 將與董事會同意的目標掛鉤。這些目標都將聚焦於能推動股東價值的具體目標。
With regard to stock option equity and, by the way, those bonus targets also were within the range established by the TPF&C executive survey that they did for us. With regard to equity in the company, each of these individuals the largest part of their pay will be derived from driving the stock price up. Mr.O'Leary has been granted a total of 1,100,000 options in ICN that is within the range and toward the lower end of the range of comparable positions.
至於股票選擇權股權部分,順帶一提,這些獎金目標也都落在 TPF&C 為我們所做的高階主管調查所建立的區間內。就公司股權而言,這些人士薪酬中最大的一部分將來自於推升股價。O'Leary 先生獲授 ICN 共 1,100,000 份選擇權,這在可比職位的區間內,且偏向該區間的較低端。
Similarly, Mr. Thiessen has been granted 1,000,000 options that also, for a President and Chief Operating Officer, is within the range. So you can see that both of those gentlemen had a significant incentive to drive shareholder value. Mr. Bailey is Chief Financial Officer's coming in with a grant of 400,000 options, again, within the competitive range.
同樣地,Thiessen 先生獲授 1,000,000 份選擇權;以總裁兼營運長而言,也在區間內。因此你可以看到,這兩位先生都有相當大的誘因去提升股東價值。Bailey 先生作為財務長,入職時獲授 400,000 份選擇權,同樣在具競爭力的區間內。
So, in summary, each of the pay packages was determined with individual advice and counsel from one of the worlds leading compensation analysts. All of the pay that has been offered is within those competitive ranges and there was a weighting put on the stock option grants to get them to focus on increasing shareholder value.
總結來說,每一份薪酬方案都是在世界頂尖薪酬分析師之一的個別建議與諮詢下所決定。所提供的所有薪酬都在這些具競爭力的區間內,並且在股票選擇權授予上加重比重,以促使他們專注於提升股東價值。
Any and all bonuses will be paid toward goals established by the board that also drives shareholder value.
任何及所有獎金都將依董事會所訂定、同樣能推動股東價值的目標來支付。
o'leary: Thank you Randy. I add too, that both the top two officers base compensation were established at levels definitely below their predecessors.
o'leary:謝謝你,Randy。我也補充一點,前兩位最高階主管的基本薪酬水準,確實是訂在明顯低於其前任的水準。
- Chairman of the Board, Viasys
- Chairman of the Board, Viasys
Thank you Rob. This is Randy. Let me reiterate that. Mr. O'Leary and Mr. Tyson's pay are below that of their predecessors in those positions.
謝謝你,Rob。我是 Randy。讓我再重申一次。O'Leary 先生與 Tyson 先生在這些職位上的薪酬,低於其前任。
And I think it says something about the potential faith in the future of the company. Mr. Bailey actually took a fairly substantial pay cut to take the job because his belief in the future potential of ICN.
我認為這也反映了他們對公司未來的潛在信心。Bailey 先生其實為了接下這份工作而大幅降薪,因為他相信 ICN 未來的發展潛力。
The second part of the question was related to our intention to manage the specialty pharmaceutical business as a separate profitable business going forward. And the answer is an unequivocal yes. Of course that's our intention. And I would say with the removal of the discontinued operations and our efforts in cost cutting, those are two formulas that in very short order will produce the kind of profitable operations from the specialty product side.
問題的第二部分是關於我們是否打算在未來把專科藥品業務作為一個獨立且可獲利的業務來經營。答案是明確的:是。當然,這就是我們的意圖。我會說,隨著剔除已終止營運,以及我們在成本削減上的努力,這兩項作法將在很短時間內,讓專科產品端產生我們所期待的獲利型營運。
That, of course, is hedged somewhat by our efforts to reduce the inventory in North America which is ongoing and will effect us into 2003.
當然,這也在某種程度上受到我們在北美降低庫存的努力所影響;該工作仍在進行中,並將影響我們直到 2003 年。
Unidentified
Unidentified
Thank you.
謝謝。
Unidentified
Unidentified
Next question please.
下一個問題,請。
Operator
Operator
Our next question comes from of Investments.
下一個問題來自Investments。
Thank you. Did you do any more debt repurchases after the quarter ended and do you expect to continue to repurchase your convertible debt?
謝謝。季度結束後你們是否又進一步回購了任何債務?你們是否預期會繼續回購你們的可轉換債?
Unidentified
Unidentified
We did not do any more debt repurchases after the quarter end and we are always considering the best use of our capital which could include additional purchases going forward.
季度結束後我們沒有再進行任何債務回購;我們一向都在評估資本的最佳用途,其中可能包括未來進一步的買回。
Thank you.
謝謝。
Operator
Operator
Next we'll hear from of Quaker Capital Management.
接下來我們將聽取Quaker Capital Management 的提問。
A couple - I'm just trying to clarify some of what was said here about the discontinued and to be discontinued businesses. I think I heard that the revenue contribution there was $45 million and I guess a couple of things here.
有幾點——我只是想釐清這裡關於已終止以及將要終止業務的一些說法。我想我聽到那部分的營收貢獻是 4,500 萬美元,我這裡有幾個問題。
One, was that - what part of that was actually reported under product sales, presumably the discontinued part which is captured in the one line, discontinued? And since there is no balance sheet, but related to this, what is the balance sheet entry for the divested assets which, presumably, is a write down close to what you think they're worth?
第一,那當中有多少實際上是列在產品銷售之下?推測應該是已終止的部分,並且被彙總在那一行「已終止」之中?另外,由於沒有資產負債表,但與此相關的是,被處分資產在資產負債表上的科目是什麼?推測應該是接近你們認為其價值的減記金額?
And what is the cash cost accrued at this point for these severance, discontinued as well as some of the residual stuff left over between the management payouts under the prior regime?
那麼,就這些遣散費、已終止營運的項目,以及前一個管理團隊制度下管理層支付之間所剩的一些殘餘項目而言,截至目前為止已應計的現金成本是多少?
Unidentified
Unidentified
OK. Great. With regards to the balance sheet, the - you can direct yourself to the table, you'll see that the on Table 2 is approximately 75 million and that's at the bottom of Table 2.
好的。很好。關於資產負債表,你可以看一下那個表格,你會看到在表2上大約是7,500萬,而且那是在表2的底部。
Right.
對。
Unidentified
Unidentified
And of that is substantially non-cash.
其中大部分是非現金項目。
Right.
對。
Unidentified
Unidentified
No more than 10 percent of that is cash related with regards to the entry, that is your entry. Going into Q4 we recorded the impairment for the businesses to be discontinued in Q3 along with the businesses that have been discontinued in Q3 and that's due to some accounting requirements. For the businesses that are to be discontinued we expect to meet those criteria in Q4 but we did record the impairment during the quarter.
其中與現金相關的部分不超過10%,就該分錄而言,那是你的分錄。進入第四季時,我們在第三季依據一些會計要求,對將要終止的業務以及在第三季已終止的業務一併認列了減損。對於將要終止的業務,我們預期在第四季會符合那些準則,但我們已在本季認列了減損。
OK. So in terms of what it's actually going to cost you to clean up all of this you're saying is only about 10 million then or say 10 percent of that 75?
好的。所以就實際上你要花多少成本把這些都處理乾淨而言,你是說大概只有1,000萬左右,或是說那7,500萬的10%?
Unidentified
Unidentified
regards to cash?
就現金而言?
Right.
對。
Unidentified
Unidentified
No it's -- I would go a little bit higher than that but it's not substantially higher in terms of the cash impact.
不,不是——我會比那個數字稍微高一點,但就現金影響而言不會高出太多。
OK and this also reflects all the charges and all the stuff from previous quarters as well?
好的,那這也反映了前幾季所有的費用與所有那些項目嗎?
Unidentified
Unidentified
Yes.
是的。
in that 20 million.
在那2,000萬裡面。
Unidentified
Unidentified
Right, well no, we have some residual amounts still outstanding from Q2 which in the range of about 20 million worth of cash that is still outstanding and then the 10 million for the items just mentioned gets you to about the right number.
對,嗯不,第二季還有一些殘餘金額尚未支付,大約有2,000萬的現金仍未支付,然後再加上剛才提到那些項目的1,000萬,就差不多是正確的數字。
OK and could you then clarify again I guess what is the balance sheet value at this point of the divested assets or to be divested and that reflect what you think you can get for them?
好的,那你能否再澄清一下,我想問的是目前已出售或將要出售資產在資產負債表上的價值是多少,並且那是否反映你認為可以賣到的價格?
Unidentified
Unidentified
When we record -- when we release our 10-Q we will have that information included. We have about, hold on just a second, there's about 20 million of residual values still on our books after you record the for the businesses to be discontinued. After that impairment the remaining residual value's approximately 20 million.
當我們發布10-Q時,我們會把那個資訊包含在內。我們大約,等一下,對於將要終止的業務在認列之後,我們帳上仍有大約2,000萬的殘餘價值。在那次減損之後,剩餘的殘餘價值大約是2,000萬。
Operator
Operator
Next we have a follow-up question from , .
接下來我們有一個追問,來自,.
Yes. The intellectual property position on ribavirin sales in the U.S. is probably the single most important factor that you have to cope with in your planning and we, obviously, have -- there's obviously a generic challenge. We've gotten input from Schering-Plough that there will be generic competition in 2003, which I think most people just don't believe will happen. The 30-month stay on expires in the second quarter of '04 and then, of course, if the method, the patents that Schering-Plough holds are valid, the patent goes out to 2015. But with all of those possibilities, what are you looking for in your planning process? What -- when are you looking for the potential for generic competition?
是的。在美國利巴韋林(ribavirin)銷售的智慧財產權地位,可能是你在規劃時必須面對的最重要單一因素,而我們顯然——也顯然存在學名藥挑戰。我們從Schering-Plough得到的資訊是,2003年會出現學名藥競爭,我想多數人都不相信會發生。對的30個月暫緩期在04年第二季到期,然後當然,如果Schering-Plough所持有的方法、專利有效,專利將延續到2015年。但在所有這些可能性之下,你在規劃流程中是怎麼看的?你們——你們預期學名藥競爭可能在什麼時候出現?
Unidentified
Unidentified
Well I'll let elaborate on our plans on the legal front. Obviously, we intend to vigorously defend but we're not going to be in the business of predicting when generic competition will be effected but as we -- but we are actively preparing to a variety of steps in the market place and with our development activities.
我會讓就我們在法律面向的計畫做更詳細的說明。顯然,我們打算積極捍衛,但我們不會去預測學名藥競爭何時會發生;不過我們——我們也正在市場端以及研發活動方面,積極準備各種措施。
Greg, any comment on the legal defense side?
Greg,在法律防禦方面有什麼評論嗎?
Unidentified
Unidentified
No. There are a multiplicity of lawsuits as you all know. And there's a great deal of speculation about the patents in the generic entries. But we really as a matter of policy can't comment on any of that pending litigation at this time. You might also, when you have the opportunity, to direct some of your questions to Ribapharm.
沒有。如各位所知,有多起訴訟。而且對於學名藥進入與相關專利有很多揣測。但基於政策,我們目前無法對任何尚在進行中的訴訟發表評論。你也可以在有機會時,把部分問題轉向Ribapharm。
o'leary: All right. Well, I guess we're at our time. We'll take one more call. The next question, please. If there are no -- if there are no more ...
o'leary:好的。我想我們時間到了。我們再接最後一通。請下一個問題。如果沒有——如果沒有更多……
Operator
Operator
We do have a question.
我們確實有一個問題。
o'leary: Oh, we do. All right. Very good.
o'leary:喔,我們有。好的。非常好。
Operator
Operator
From of Partners.
來自的Partners。
o'leary: OK, .
o'leary:好的,.
Thank you. A followup on the debt repurchases ...
謝謝。關於回購債務的追問……
Unidentified
Unidentified
Yes, sir?
是的,先生?
You said you bought 60 million of the converts at a gain of about $11 million, which implies an $82.00 price free -- bonds are trading quite a bit below that now.
你說你以約1,100萬美元的收益買回了6,000萬的可轉債,這意味著價格約為82.00美元——而債券現在的交易價格遠低於那個水準。
Unidentified
Unidentified
Yes, that's ...
是的,那是……
... curious as to why you haven't continued to make repurchases.
……好奇你為什麼沒有繼續回購。
Unidentified
Unidentified
Yes, that's a net of tax number -- the 10 million. No, they were bought in the 60's, which were at market prices at the time we were entering the market. And with regards to additional purchases we're considering that. Keep in mind, the Company has a policy with regards to trading windows and those policies applied not only to its purchase of some shares when those activities occurred, but also to the repurchases of its own bond.
是的,那個1,000萬是稅後淨額——也就是那個數字。不,它們是在60多(美元)的價位買的,當時我們進場時是按當時的市價買入。至於進一步的買入,我們正在考慮。請記住,公司對交易窗口有相關政策,這些政策不僅適用於當時進行的一些股票買入活動,也適用於回購自家債券。
I see. OK. Thank you.
我明白了。好的。謝謝。
o'leary: OK, thank you, . Appreciate that. I want to thank all of you for joining us on the call today. We look forward to speaking with you all again. And I look forward, particularly, to introducing you to both Tim Tyson and Bary Bailey. I think you will enjoy getting to know them and find them very helpful.
o'leary:好的,謝謝你,.感謝。我要感謝各位今天參加電話會議。我們期待再次與各位交流。我也特別期待向各位介紹Tim Tyson和Bary Bailey兩位。我想你們會很享受認識他們,並覺得他們非常有幫助。
I want to thank my colleagues here at ICN and Randy Thurman and Adam Jerney as well. We look forward to speaking with you all again in the near future to share, hopefully, are progress these. And we will be reporting -- before we are next formally together -- against our progress against the targets we've set out there. Thank you all and good morning.
我也要感謝我在ICN的同事,以及Randy Thurman和Adam Jerney。我們期待在不久的將來再次與各位交流,並希望能分享我們在這些方面的進展。而且在我們下次正式再聚之前——我們將會就我們朝著所設定目標的進展進行報告。謝謝各位,早安。
Operator
Operator
That does conclude today's conference call. We thank you all for your participation.
今天的電話會議到此結束。感謝各位的參與。